Urigen Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - August 10, 2012

Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - Urigen Pharmaceuticals, Inc.ex321.htm
EX-31.1 - EXHIBIT 31.1 - Urigen Pharmaceuticals, Inc.ex311.htm
EX-21.1 - EXHIBIT 21.1 - Urigen Pharmaceuticals, Inc.ex211.htm
EX-10.27 - EXHIBIT 10.27 - Urigen Pharmaceuticals, Inc.ex1027.htm
EX-10.35 - EXHIBIT 10.35 - Urigen Pharmaceuticals, Inc.ex1035.htm
EX-10.31 - EXHIBIT 10.31 - Urigen Pharmaceuticals, Inc.ex1031.htm
10-K - URIGEN PHARMACEUTICALS, INC. FORM 10-K - Urigen Pharmaceuticals, Inc.form10k.htm
Exhibit 23.1
 

 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
We hereby consent to the use in the Registration Statements on Form S-8 (File No. 333-105828, 333-111944 and 333-123208) pertaining to the Amended and Restated 1997 Equity Incentive Plan and the Amended and Restated 1998 Non-Employee Directors’ Stock Option Plan of Urigen Pharmaceuticals, Inc. of our report (which contains an explanatory paragraph relating to Urigen Pharmaceuticals, Inc.’s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) dated August 9, 2012, relating to the consolidated financial statements of Urigen Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended June 30, 2010.
 
 
/s/ Burr Pilger Mayer, Inc.
 
 
E. Palo Alto, California
 
August 9, 2012

Urigen Pharmaceuticals, Inc. Reports

Also read